These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 2109679)

  • 1. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
    Brogden RN; Buckley MM; Ward A
    Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of LHRH and its analogues.
    Sandow J
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):571-92. PubMed ID: 6136347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Yen SS
    Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1990 Apr; 39(4):523-51. PubMed ID: 2140979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
    Spicer DV; Pike MC; Pike A; Rude R; Shoupe D; Richardson J
    Contraception; 1993 May; 47(5):427-44. PubMed ID: 8390340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
    Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH analogues for contraception.
    Fraser HM
    Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of antagonistic analogs of LH-RH as a contraceptive method in the female.
    Schally AV
    Res Front Fertil Regul; 1983 Jul; 2(5):1-16. PubMed ID: 12179624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A; Quesnel G
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsatile control of reproduction.
    Lancet; 1984 Aug; 2(8399):382-3. PubMed ID: 6147459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review.
    Thau RB
    Contraception; 1984 Feb; 29(2):143-62. PubMed ID: 6426857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel peptides in ovarian follicular fluid: implications for contraceptive development.
    Schwartz NB
    Res Front Fertil Regul; 1982 Sep; 2(2):1-11. PubMed ID: 12179632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic uses of gonadotropin-releasing hormone analogs.
    Andreyko JL; Marshall LA; Dumesic DA; Jaffe RB
    Obstet Gynecol Surv; 1987 Jan; 42(1):1-21. PubMed ID: 3543765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.